1. Wedelolactone Mitigates Parkinsonism Via Alleviating Oxidative Stress and Mitochondrial Dysfunction Through NRF2/SKN-1.
- Author
-
Sharma S, Trivedi S, Pandey T, Ranjan S, Trivedi M, and Pandey R
- Subjects
- Animals, Animals, Genetically Modified, Antioxidants metabolism, Behavior, Animal drug effects, Caenorhabditis elegans drug effects, Caenorhabditis elegans genetics, Coumarins pharmacology, Dopamine metabolism, Gene Expression Regulation drug effects, Lipids chemistry, Mitochondria drug effects, Parkinsonian Disorders genetics, Protein Aggregates drug effects, Protein Carbonylation drug effects, Reactive Oxygen Species metabolism, Stress, Physiological drug effects, Stress, Physiological genetics, alpha-Synuclein metabolism, Caenorhabditis elegans metabolism, Caenorhabditis elegans Proteins metabolism, Coumarins therapeutic use, DNA-Binding Proteins metabolism, Mitochondria pathology, NF-E2-Related Factor 2 metabolism, Oxidative Stress drug effects, Oxidative Stress genetics, Parkinsonian Disorders drug therapy, Parkinsonian Disorders pathology, Transcription Factors metabolism
- Abstract
Parkinsonism is an age-associated neurodegenerative disorder characterized by aggregation of α-synuclein (α-syn) protein in the substantia nigra region, degeneration of dopaminergic neurons, and deregulated lipid metabolism. Currently, only symptomatic relief has been provided by FDA-approved therapeutic approaches for Parkinson's disease (PD). The present study aims to evaluate the potential of wedelolactone (WDL), a natural occurring coumestan found in Eclipta alba to mitigate the parkinsonism in Caenorhabditis elegans disease model. In the present studies, supplementation with 37.5 μM WDL exhibited a reduction in the level of α-syn in an age-dependent manner (22% at day 5, p < 0.05; and 16% at day 10, p < 0.001, n = 30), along with improvement in neuronal health through basal movement, and elevated the dopamine levels evident through 1-nonanol repulsion results in wild-type and diseased worms. Moreover, WDL augmented the mitochondrial health in wild-type, PD-diseased, and mev-1 mutant worms that establish the inherent activity of WDL in the alleviation of oxidative stress. Furthermore, WDL supplementation significantly decreases the neutral lipid and triglyceride level and also alleviates protein carbonyl level in PD disease condition. The overall investigation will provide a pioneer to the future insights of PD research related to plant-based drugs. qPCR studies after WDL supplementation revealed alteration of genes involved in the regulation of various stress-responsive (sod-5, gst-4, skn-1), α-syn-suppressing (lrk-1, ymel-1, lagr-1, grk-1), and mitochondrial (pink-1) genes. All together, these findings support that the WDL is a promising candidate to combat age-related multi-factorial PD pathology associated with protein misfolding and accumulation. The results provide sufficient information in the development of therapeutic medicines from natural products for improving the health.
- Published
- 2021
- Full Text
- View/download PDF